Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans

University of Aarhus

Status: Completed

Conditions: Muscle Injury

Treatments: Other: Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily); Other: Placebo (twice daily)

Study type: Interventional

Funder types: Other

Identifiers

NCT03754842

AU2018-11-19

Details and patient eligibility

About

Successful skeletal muscle regeneration depends on a functional pool of muscle stem cells, termed satellite cells (SC). SC are in a quiescent state throughout adulthood, but undergo multiple cycles of proliferation and self-renewal in response to muscle damage. During aging, there is a loss of SC quiescence, and SC more readily enter an ageing-state impairing their function.

Animal studies have revealed a common denominator for increasing SC function and activity, namely Sirtuin activation. Natural stimulators of Sirtuins includes Nicotinamide Riboside (NR) (a Nicotinamide adenine dinucleotide (NAD+) precursor) and the polyphenol Pterostilbene (PT). In this study, we aim to investigate if NR+PT supplementation will promote skeletal muscle regeneration after muscle damage in elderly humans by enhanced recruitment of SC.

Full description

14 days after start of placebo or NR/PT (500/100 mg twice daily) supplementation a muscle damage will induced in the m. vastus lat. by electric stimulation combined with eccentric work in a dynamometer. Muscle biopsies will be collected at 2 hours, 2, 8 and 30 days post damage and placebo or NR/PT supplementation will continue for the whole study period (45 days).

Enrollment: 32 patients

Sex: All

Ages: 55 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Written signed consent
• Age: 55-80
• BMI: 20-28 (kg/(m2))
• Non-smoker

Exclusion criteria

• Endocrine disease, neurological or muscle disease
• Other severe disease
• High daily activity level (>30 min / day)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

32 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Treatment:

Other: Placebo (twice daily)

Nicotinamide Riboside + Pterostilbene

Experimental group

Treatment:

Other: Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)